Chronic Hepatitis C
HEPATITIS C --- Navigation Topics
• Top New Articles on HCV
• All HCV Articles by Topic ( A to Z )
• HCV Basics
• HIV-HCV Coinfection
• FDA-approved Treatments for HCV
- Roferon A (interferon alfa-2a)
- Intron A (interferon alfa-2b)
- Infergen (consensus interferon)
- Pegasys (peginterferon alfa-2a)
- PegIntron (peginterferon alfa-2b)
- Copegus / Rebetol (ribavirin)
- Intron A + Rebetol
- Roferon A + Ribavirin
- Pegasys + Copegus
- PegIntron + Rebetol
• Treatment Guidelines for HCV
• Experimental Treatments for HCV
• Recent Research Conference Reports
• Tests for HCV
• Liver-related Complications
• Drug-related Adverse Events
• Doctor Is In 'Q and A' for HCV
• Library of CME Programs
• E-mail Update - Sign Up
• About Us - Contact Us
_______________
Dose Reductions for Interferon and/or Ribavirin
Ribavirin Main Page
Does Weight-based Ribavirin
Dosing Increase Sustained Viral Response in Patients with Chronic Hepatitis C? Final Results of the WIN-R Study
- 11/18/05
A
Dose Escalation
Study of Merimepodib (VX-497) Plus Interferon Alfa among Treatment-naïve HCV Patients
- 9/23/05
Treatment of Patients with Advanced Hepatitis C with a Low Accelerating
Dosage Regimen
of Peginterferon/Ribavirin Can Result in Favorable Clinical Outcomes
- 9/21/05
High-dose Induction
Therapy with Interferon Alfa-2b (PegIntron) Plus Ribavirin for Treatment of Relapsers or Nonresponders
- 9/19/05
Optimal Dosing Frequency of Pegylated Interferon Alfa-2b (PegIntron) Monotherapy
- 6/29/05
Filgrastim for the Neutropenia Associated with Combination Therapy in Chronic Hepatitis C
- 6/01/05
Treatment of HCV in Cirrhotic Patients
- 4/25/05
12-Week Virology Predicts SVR in Nonresponders Receiving Interferon Alfa-2b (PegIntron) Plus Ribavirin (Rebetol)
Weight-based Dosing
- 4/18/05
Avoiding Ribavirin Dose Reductions and
Dose Discontinuations
Likely Will Improve Overall SVR in Gentotype 1 Chronic Hepatitis C
- 4/15/05
Viramidine Demonstrates Anti-HCV Genotype 1 Activity That Compares to That of
Ribavirin
, But without Complications of Severe Anemia
- 4/15/05
Avoiding
Ribavirin
Dose Reductions and Dose Discontinuations Likely Will Improve Overall SVR in Gentotype 1 Chronic Hepatitis C
- 4/15/05
Impact of Obesity on the Degree of Liver Disease and Response to Therapy in Chronic HCV Patients
- 4/15/05
Ribavirin Plays Critical Role in the Response to Peginterferon-based Anti-HCV Therapy
- 2/28/05
High-dose
Vitamin E Does Not Reduce Ribavirin-associated Anemia in Treatment of HCV with Standard Interferon Alfa and Ribavirin
- 2/07/05
HIV AND AIDS
|
HEPATITIS B
|
HEPATITIS C
|
HIV / HBV CO-INFECTION
|
HIV / HCV CO-INFECTION
|
HEALTH AND TECHNO
LOGY
|
TESTS
|
INTERNET CONFERENCE REPORTS
|
TELECONFERENCES
|
LINKS
|
ABOUT US
|
CONTACT US
